UK drug-pricing watchdog recommends Novartis CAR-T for leukemia in final draft guidance
NICE recommends Kymriah to the Cancer Drugs Fund due to remaining questions about evidence to support it, but believes those questions will be resolved.
Novartis, Gilead, Celgene/Agios blood cancer treatments sweep Prix Galien awards
Along with Boston Scientific's Watchman in the technology category, Novartis and Gilead's Kite shared the biotechnology award for CAR-T therapy, while Celgene/Agios's Idhifa won the pharmaceutical prize.
presented by
How (and Where) to Find the Best Value Rehabilitation Programs for Brain Injuries
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
Recently published CAR-T mishap could pose challenges for Novartis, Gilead and others
A manufacturing error during a clinical trial of Kymriah, now marketed by Novartis, is less likely today, but could be an issue as CAR-Ts move into earlier therapy lines.
CBMG to manufacture CAR-T Kymriah for Chinese market under partnership with Novartis
The deal will bring the CAR-T therapy to China's burgeoning market, but it faces competition from Gilead's Yescarta - manufactured under a JV with Fosun - and also homegrown products.
J&J to enter Chinese CAR-T for myeloma into Phase Ib/II trial
The clinical trial of the CAR-T - a potential competitor to bluebird bio's - will start enrolling patients later this year.
The cost of gene therapy for patients goes well beyond the drug’s price
“If you’ve paid half a million dollars for drugs and half a million dollars for care, and a year later your cancer is back, is that a good deal?” asked Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York.
presented by
The Top EAP Companies for Mental Health Support
Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.
Notable Labs raises $10M for drug testing service to develop therapeutic index for oncologists
The goal of the business is to help physicians identify the most suitable combinations of FDA-approved treatments that can be immediately prescribed.
Cellular therapy just got real: Novartis is the first to get FDA approval for CAR-T treatment (Updated)
At $475,000, the therapy isn't cheap but for its part, Novartis has said patients would only pay the full whack if they respond to the therapy by the end of the first month.
Will a new leukemia drug from Novartis be a quantum leap for cancer drug prices?
“From what we’re hearing, this will be a quantum leap more expensive than other cancer drugs,” said Leonard Saltz, chief of gastrointestinal oncology at Memorial Sloan Kettering Cancer Center in New York.
Small-molecule tool could reduce leukemia cell regeneration
“We showed that cancer stem cells co-opt an RNA editing system to clone themselves. What’s more, we found a method to dial it down,” said principal investigator Dr. Catriona Jamieson, of UC San Diego School of Medicine.
presented by
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Morning Read: Jazz Pharma makes $1.5B offer for Celator for acute myeloid leukemia drug
Also, the College of Healthcare Information Executives has created the CHIME Cybersecurity Center and Program Office, and ProofPilot CEO talks about the challenge of balancing digital health startup investor expectations with those of customers.
Can you beat cancer? It depends on where you live
With information from one of the most intense cancer research studies ever conducted (surveying 25.7 million people), it’s clear that where you live has something to do with how likely you are to survive cancer. For example, 9 out of 10 kids with lymphblastic leukemia in the U.S. will survive. Compare that to the 16 […]
Cancer drug firm Oncotide develops compounds that may restore cells’ tumor-suppressing abilities
Cancer cells are sneaky and, unfortunately, smart enough to develop a host of ways to escape the body’s defense mechanisms. A startup called Oncotide Pharmaceuticals is hoping to outsmart some cancer cells by modulating a certain kind of protein phosphatase that impedes the ability of cancer cells to grow and replicate. That phosphatase is PP2A, […]
GSK leukemia treatment Arzerra filed for regulatory approval in Japan
Leukemia treatment Arzerra, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Genmab (CSE:GEN), has been submitted for approval in Japan. Arzerra has currently received regulatory approval in the United States and Europe to treat chronic lymphocytic leukemia (CLL), a type of leukemia that progresses more slowly as it targets lymphocytes in the body’s immune system. CLL […]
HTLV blood screening test from RTP diagnostics firm Avioq gets FDA OK
The U.S. Food and Drug Administration has approved a new test for blood donations, just the second test available to screen for two viruses linked to leukemia and neurologic disorders. The blood test, developed by medical device company Avioq, detects antibodies to human T-lymphotropic virus type 1 (HTLV 1) and human T-lymphotropic virus type 2 […]